Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers.

Infection is a common problem and has become one of the leading causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). The reasons for the high incidence of infection are immunosuppressive therapy and immune disturbances of lupus itself. Infections may mimic exacerbations of SLE, leading to confusion over the diagnosis and appropriate treatment. It can be notoriously difficult to differentiate between infection and disease flare in some cases. Indeed they may co-exist. Along with the conventional biomarkers of lupus flares as hypocomplementemia, anti-double-stranded-DNA antibodies and erythrocyte sedimentation rate, other biomarkers as procalcitonin, and autoantibodies against complement fraction C1q, have been investigated to distinguish infections from other inflammatory processes. Recent research has provided data about new potential biomarkers to assist clinical decision-making in the management of SLE patients (e.g. percentage of circulating CD27 high plasma cells from the peripheral blood, 2'5'-oligoadenylate synthetase isoforms, soluble triggering receptor expressed on myeloid cells-1 and pentraxin 3), but only some of them are supported by convincing evidence, such as CD 64-Fc receptor expression. We reviewed the literature on the available tests to discriminate between SLE activity and infections, focusing on conventional and upcoming biomarkers.

[1]  I. Buhăescu,et al.  Serum procalcitonin in systemic autoimmune diseases--where are we now? , 2010, Seminars in arthritis and rheumatism.

[2]  Y. Shoenfeld,et al.  Infections and SLE , 2005, Autoimmunity.

[3]  M. Haubitz,et al.  Elevation of serum CXCL13 in SLE as well as in sepsis , 2011, Lupus.

[4]  M. Haubitz,et al.  B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  N. Hogg,et al.  The effect of IFN-gamma and colony-stimulating factors on the expression of neutrophil cell membrane receptors. , 1989, Journal of immunology.

[6]  R. Friedman,et al.  Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon , 1983, The Journal of experimental medicine.

[7]  F. Houssiau.  Management of lupus nephritis: an update. , 2004, Journal of the American Society of Nephrology : JASN.

[8]  Anthony S McLean,et al.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[9]  T. Vogl,et al.  Phagocyte-specific S100A8/A9 Protein Levels During Disease Exacerbations and Infections in Systemic Lupus Erythematosus , 2009, The Journal of Rheumatology.

[10]  D. D'cruz,et al.  Acute Viral Infections in Patients With Systemic Lupus Erythematosus: Description of 23 Cases and Review of the Literature , 2008, Medicine.

[11]  H. Leu,et al.  Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review. , 2007, Rheumatology.

[12]  P. Coriat,et al.  Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery , 2008, Critical care medicine.

[13]  B. Davis.  Improved diagnostic approaches to infection/sepsis detection , 2005, Expert review of molecular diagnostics.

[14]  M. Brown,et al.  Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis , 2009, Arthritis research & therapy.

[15]  H. Moutsopoulos,et al.  High C-reactive protein response in lupus polyarthritis. , 1983, Clinical and experimental rheumatology.

[16]  M. Ramos-Casals.  Viruses and lupus: the viral hypothesis , 2008, Lupus.

[17]  C. Garlanda,et al.  Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. , 2009, Clinical and experimental rheumatology.

[18]  R. Bojalil,et al.  C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. , 2011, Clinical laboratory.

[19]  D. Berel,et al.  High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus , 2011, Lupus.

[20]  J. Reveille,et al.  Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. , 2005, The Journal of rheumatology.

[21]  A. Cats,et al.  The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. , 1985, Arthritis and rheumatism.

[22]  K. Nishimura,et al.  Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. , 2008, The Journal of rheumatology.

[23]  Karin Reiter,et al.  Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[24]  A. Mantovani,et al.  High circulating levels of the IL‐1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration , 2002, Journal of leukocyte biology.

[25]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[26]  M. Haubitz,et al.  Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. , 1997, Arthritis and rheumatism.

[27]  P. Lipsky,et al.  Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus , 2004, Lupus.

[28]  Shun-le Chen,et al.  Could 2′5′-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot study , 2006, Clinical Rheumatology.

[29]  V. Strand,et al.  Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[30]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Schmidt,et al.  The high‐affinity FcγRI on PMN: regulation of expression and signal transduction , 1997, Immunology.

[32]  G. Hughes,et al.  Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[33]  C. Suh,et al.  C-reactive Protein Is a More Sensitive and Specific Marker for Diagnosing Bacterial Infections in Systemic Lupus Erythematosus Compared to S100A8/A9 and Procalcitonin , 2012, The Journal of Rheumatology.

[34]  T. Vischer,et al.  Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. , 1993, The Journal of rheumatology.

[35]  F. Skopouli.  Kidney injury in Sjögren's syndrome. , 2001, Nephrology, Dialysis and Transplantation.

[36]  F. Irshaid,et al.  The complex nature of serum C3 and C4 as biomarkers of lupus renal flare , 2010, Lupus.

[37]  Fu-Huang Lin,et al.  Significantly Higher Percentage of Circulating CD27high Plasma Cells in Systemic Lupus Erythematosus Patients with Infection than with Disease Flare-Up , 2010, Yonsei medical journal.

[38]  M. Christ-Crain,et al.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[39]  M. Petri,et al.  Renal biopsy in lupus patients with low levels of proteinuria. , 2007, The Journal of rheumatology.

[40]  T. Satoh,et al.  Clinical and laboratory features of lupus patients with complicating pulmonary disease. , 1999, Respiratory medicine.

[41]  J. Cameron,et al.  Lupus Nephritis , 1959, Clinics in rheumatic diseases.

[42]  A. Deodhar,et al.  Neutrophil CD64 expression: distinguishing acute inflammatory autoimmune disease from systemic infections , 2002, Annals of the rheumatic diseases.

[43]  H. Baek,et al.  Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE , 2001, Annals of the rheumatic diseases.

[44]  A. Iglesias,et al.  The Use of Procalcitonin Determinations in Evaluation of Systemic Lupus Erythematosus , 2008, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[45]  Federica Sallusto,et al.  Follicular B Helper T Cells Express Cxc Chemokine Receptor 5, Localize to B Cell Follicles, and Support Immunoglobulin Production , 2000, The Journal of experimental medicine.

[46]  C. Bao,et al.  Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1. , 2003, Rheumatology.

[47]  D. Gladman,et al.  Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. , 1991, The Journal of rheumatology.

[48]  M. A. Eltoukhy,et al.  Neutrophil CD64 Expression in Inflammatory Autoimmune Diseases: Its Value in Distinguishing Infection from Disease Flare , 2010, Immunological investigations.

[49]  P. Ljungman.  Risk assessment in haematopoietic stem cell transplantation: viral status. , 2007, Best practice & research. Clinical haematology.

[50]  G. Alarcón,et al.  Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. , 2003, Rheumatic diseases clinics of North America.

[51]  F. Betsou,et al.  Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus , 2011, Lupus.